We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > orphan diseases

News List

Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases firstwordpharma
July 28, 2021
Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced the closing of a $63 million Series B financing.
Low awareness of rare diseases increases morbidity and potential mortality pharmaceutical-technology
June 02, 2021
Orphan or rare diseases are conditions that affect a small percentage of the population in a given country. The widely accepted definition in the US is a disease that affects fewer than 200,000 people nationwide.
Minoryx Therapeutics completes phase 1 clinical trial for MIN-102 biospectrumasia
March 23, 2017
MIN-102 was well-tolerated at much higher doses than those required for efficacy